Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;2008:385108.
doi: 10.1155/2008/385108.

C-Peptide and Atherogenesis: C-Peptide as a Mediator of Lesion Development in Patients With Type 2 Diabetes Mellitus?

Affiliations
Free PMC article
Review

C-Peptide and Atherogenesis: C-Peptide as a Mediator of Lesion Development in Patients With Type 2 Diabetes Mellitus?

Nikolaus Marx et al. Exp Diabetes Res. .
Free PMC article

Abstract

Patients with insulin resistance and early type 2 diabetes exhibit an increased propensity to develop a diffuse and extensive pattern of arteriosclerosis. Typically, these patients show increased levels of C-peptide and over the last years various groups examined the effect of C-peptide in vascular cells as well as its potential role in lesion development. While some studies demonstrated beneficial effects of C-peptide, for example, by showing an inhibition of smooth muscle cell proliferation, others suggested proatherogenic mechanisms in patients with type 2 diabetes. Among them, C-peptide may facilitate the recruitment of inflammatory cells into early lesions and promote lesion progression by inducing smooth muscle cell proliferation. The following review will summarize the effects of C-peptide in vascular cells and discuss the potential role of C-peptide in atherogenesis in patients with type 2 diabetes.

Figures

Figure 1
Figure 1
Potential role of C-peptide in early atherogenesis in patients with insulin resistance and early type 2 diabetes mellitus. During endothelial dysfunction with increased endothelial permeability, C-peptide could deposit in the intima and through its chemotactic activity on monocytes and CD4+ lymphocytes facilitate the recruitment of these inflammatory cells into the vessel wall.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

References

    1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. Journal of the American Medical Association. 2002;287(19):2570–2581. - PubMed
    1. Wahren J, Ekberg K, Jörnvall H. C-peptide is a bioactive peptide. Diabetologia. 2007;50(3):503–509. - PubMed
    1. Wahren J, Shafqat J, Johansson J, Chibalin A, Ekberg K, Jörnvall H. Molecular and cellular effects of C-peptide—new perspectives on an old peptide. Experimental Diabetes Research. 2004;5(1):15–23. - PMC - PubMed
    1. Kitamura T, Kimura K, Jung BD, et al. Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein. Biochemical Journal. 2001;355, part 1:123–129. - PMC - PubMed
    1. Kitamura T, Kimura K, Jung B-D, et al. Proinsulin C-peptide activates cAMP response element-binding proteins through the p38 mitogen-activated protein kinase pathway in mouse lung capillary endothelial cells. Biochemical Journal. 2002;366, part 3:737–744. - PMC - PubMed

Publication types

Feedback